Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study shows combination of immune substances to be safe

12.12.2005


New research has shown that the immune-stimulating hormone known as interleukin-12 (IL-12) can safely be administered with interferon, another immune-system protein, as an experimental therapy for some cancers.



Normally, interferon is used alone to stimulate the immune system to attack certain cancers. This strategy, a form of immunotherapy, is sometimes used to treat melanoma, advanced kidney cancer and other tumors that respond poorly to chemotherapy or radiation therapy. But interferon can have serious side effects that limit its use.

Surprisingly, the two drugs used in sequence caused no serious side effects in patients.


"Interferon can be quite toxic when used alone," says principal investigator William E. Carson, III, associate professor of surgery and associate director for clinical research at the Ohio State University Comprehensive Cancer Center.

"We were initially concerned that the addition of IL-12 might increase that toxicity. Instead, we found that the two drugs can be used together without additional side effects."

The findings are published in the December 1 issue of the Journal of Clinical Oncology. They suggest that IL-12 primes white blood cells such that a lower dose of interferon will stimulate the same level of immune activity as a higher dose of interferon when used alone.

The results come from a phase-I clinical trial, which marks the first time a treatment is tried in human subjects. The trial, conducted by Carson and a team of colleagues, involved 49 patients ages 23 to 84 with different types of advanced cancer, including cancers of the colon, lung, kidney and bladder and melanoma.

On the first day of treatment, patients were given IL-12, initially by injection and then intravenously. That was followed by injections of interferon over the next five days. On average, patients received five such cycles over the course of the study.

The drug combination not only proved to be safe – which was the purpose of the study – but the researchers found that it stopped disease progression in five of the patients for at least six months.

"Our findings were encouraging," Carson says. "They indicate that we can safely administer IL-12 in combination with interferon, that it enhances the action of interferon in some patients with advanced cancer, and that it can be an effective way to stimulate the immune system."

Based on the study’s results, and the results of earlier animal studies led by the research group, Carson and his colleagues are conducting a multicenter phase II clinical trial of the two drugs in people with melanoma.

Phase-II trials are the first step in determining the effectiveness of new therapy against a specific disease.

"We believe that use of the two drugs together will give us more bang for the buck," says first author Gregory B. Lesinski, a research assistant professor in the Human Cancer Genetics Program.

"We hope that the IL-12 will allow us to use lower doses of interferon in patients, which should result in fewer side effects and potentially a longer use of interferon, giving the immune system more time to fight the tumor."

Darrell E. Ward | EurekAlert!
Further information:
http://www.osumc.edu

More articles from Studies and Analyses:

nachricht Study relating to materials testing Detecting damages in non-magnetic steel through magnetism
23.07.2018 | Technische Universität Kaiserslautern

nachricht Innovative genetic tests for children with developmental disorders and epilepsy
11.07.2018 | Christian-Albrechts-Universität zu Kiel

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: It’s All in the Mix: Jülich Researchers are Developing Fast-Charging Solid-State Batteries

There are currently great hopes for solid-state batteries. They contain no liquid parts that could leak or catch fire. For this reason, they do not require cooling and are considered to be much safer, more reliable, and longer lasting than traditional lithium-ion batteries. Jülich scientists have now introduced a new concept that allows currents up to ten times greater during charging and discharging than previously described in the literature. The improvement was achieved by a “clever” choice of materials with a focus on consistently good compatibility. All components were made from phosphate compounds, which are well matched both chemically and mechanically.

The low current is considered one of the biggest hurdles in the development of solid-state batteries. It is the reason why the batteries take a relatively long...

Im Focus: Color effects from transparent 3D-printed nanostructures

New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference

Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

LaserForum 2018 deals with 3D production of components

17.08.2018 | Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

 
Latest News

Quantum bugs, meet your new swatter

20.08.2018 | Information Technology

A novel synthetic antibody enables conditional “protein knockdown” in vertebrates

20.08.2018 | Life Sciences

Metamolds: Molding a mold

20.08.2018 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>